(Total Views: 604)
Posted On: 03/15/2021 5:09:31 PM
Post# of 148899
Roche’s Actemra (Tocilizumab) Fails to Meet Endpoints in REMDACTA Trial
Trialsite news reported this:
Although some studies have evidenced to the contrary, the anti-inflammatory drug called Actemra combined with Veklury (remdesivir) did not lead to reduced hospitalization as has been determined via data from the REMDACTA trial, which looked at the cocktail only remdesivir and standard of care. Moreover, the clinical trial revealed that the Actemra-remdesivir combination failed to achieve secondary targets, such as failing to reduce the probability that a patient would need support from mechanical ventilation or reducing the mortality rate. Roche’s Levi Garraway declared, “Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints.” While Roche is on the record that the “totality of the data” involving their drug encompassing results from, other data evidences the drug can help at least select patients. Mixed study results lead to varied responses from various medicinal evidence bodies: in some countries, ACTEMRA is embraced for at least select conditions associated with COVID-19 while in other nations, the door is shut. Germany is an example of the latter where the Association of Medical Societies recommends against usage of Actemra for severe COVID-19 while in the U.S., the drug is recommended in select patient cases in hospital or intensive care scenarios.
The drug is approved for rheumatoid arthritis and used in some scenarios involving cancer and adverse immune response post cell therapy. By 2020, the drug became Roche’s fifth top product as measured by revenue—about $3 billion with $600 million deriving from application to treat SARS-CoV-2 infection.
https://trialsitenews.com/roches-actemra-toci...pneumonia/
Here is Roche's PR
https://www.roche.com/media/releases/med-cor-2021-03-11.htm
I appreciate CDiddy's effort to keep the board focused on Leronlimab, but failure of a competitor seems relevant to me.
Trialsite news reported this:
Although some studies have evidenced to the contrary, the anti-inflammatory drug called Actemra combined with Veklury (remdesivir) did not lead to reduced hospitalization as has been determined via data from the REMDACTA trial, which looked at the cocktail only remdesivir and standard of care. Moreover, the clinical trial revealed that the Actemra-remdesivir combination failed to achieve secondary targets, such as failing to reduce the probability that a patient would need support from mechanical ventilation or reducing the mortality rate. Roche’s Levi Garraway declared, “Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints.” While Roche is on the record that the “totality of the data” involving their drug encompassing results from, other data evidences the drug can help at least select patients. Mixed study results lead to varied responses from various medicinal evidence bodies: in some countries, ACTEMRA is embraced for at least select conditions associated with COVID-19 while in other nations, the door is shut. Germany is an example of the latter where the Association of Medical Societies recommends against usage of Actemra for severe COVID-19 while in the U.S., the drug is recommended in select patient cases in hospital or intensive care scenarios.
The drug is approved for rheumatoid arthritis and used in some scenarios involving cancer and adverse immune response post cell therapy. By 2020, the drug became Roche’s fifth top product as measured by revenue—about $3 billion with $600 million deriving from application to treat SARS-CoV-2 infection.
https://trialsitenews.com/roches-actemra-toci...pneumonia/
Here is Roche's PR
https://www.roche.com/media/releases/med-cor-2021-03-11.htm
I appreciate CDiddy's effort to keep the board focused on Leronlimab, but failure of a competitor seems relevant to me.
(6)
(0)Scroll down for more posts ▼
